Etrolizumab for ulcerative colitis: the new kid on the block?

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19;361(21):2066–2078.
   PubMed Web of Science ®Google Scholar
• Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012 Nov 3;380(9853):1606–1619.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013 Feb;58(2):519–525. doi:10.1007/s10620-012-2371-5.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 1;142(1):46–54.e42.
   PubMed Web of Science ®Google Scholar
• Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am. 2002 Mar;31(1):147–166.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Iskandar HN, Dhere T, Farraye FA. Ulcerative colitis: update on medical management. Curr Gastroenterol Rep. 2015 Nov;17(11):44.
   PubMedGoogle Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012 Dec;6(10):991–1030.
   PubMed Web of Science ®Google Scholar
• Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014 Jan;57(1):5–22.
   PubMed Web of Science ®Google Scholar
• Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics. 2013;7:123–130.
   PubMedGoogle Scholar
• Ali T, Kaitha S, Mahmood S, et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79–99. doi:10.2147/DHPS.S28801.
   PubMedGoogle Scholar
• Bickston SJ, Behm BW, Tsoulis DJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD007571. doi:10.1002/14651858.CD011275.
   PubMedGoogle Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012 Jun;61(6):918–932.
   PubMed Web of Science ®Google Scholar
• Behm BW, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2009(1). Article No. CD007571. doi:10.1002/14651858.CD007571.
   PubMed Web of Science ®Google Scholar
• Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999 Dec;45(6):856–863.
   PubMed Web of Science ®Google Scholar
• Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005 Oct 17;202(8):1063–1073.
   PubMed Web of Science ®Google Scholar
• Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med. 2005 Oct 17;202(8):1051–1061.
   PubMed Web of Science ®Google Scholar
• Ruane DT, Lavelle EC. The role of CD103(+) dendritic cells in the intestinal mucosal immune system. Front Immunol. 2011;2:25. doi:10.3389/fimmu.2011.00025.
   PubMed Web of Science ®Google Scholar
• Lin KK, Mahadevan U. Etrolizumab: anti-beta7-a novel therapy for ulcerative colitis. Gastroenterology. 2014 Jan;146(1):307–309. doi:10.1053/j.gastro.2013.11.013.
   PubMedGoogle Scholar
• Stefanich EG, Danilenko DM, Wang H, et al. A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162(8):1855–1870.
   PubMed Web of Science ®Google Scholar
• Gurish MF, Tao H, Abonia JP, et al. Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing. J Exp Med. 2001 Nov 5;194(9):1243–1252.
   PubMed Web of Science ®Google Scholar
• Butcher EC, Williams M, Youngman K, et al. Lymphocyte trafficking and regional immunity. Adv Immunol. 1999;72:209–253.
   PubMed Web of Science ®Google Scholar
• Cepek KL, Parker CM, Madara JL, et al. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunology. 1993 Apr 15;150(8 Pt 1):3459–3470.
   PubMed Web of Science ®Google Scholar
• Higgins JM, Mandlebrot DA, Shaw SK, et al. Direct and regulated interaction of integrin alphaEbeta7 with E-cadherin. J Cell Biol. 1998 Jan 12;140(1):197–210.
   PubMed Web of Science ®Google Scholar
• Karecla PI, Bowden SJ, Green SJ, et al. Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol. 1995 Mar;25(3):852–856. doi:10.1002/eji.1830250333.
   PubMed Web of Science ®Google Scholar
• Parker CM, Cepek KL, Russell GJ, et al. A family of beta 7 integrins on human mucosal lymphocytes. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1924–1928.
   PubMed Web of Science ®Google Scholar
• Demetter P, De Vos M, Van Damme N, et al. Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol. 2000 Sep;114(3):364–370.
   PubMed Web of Science ®Google Scholar
• Elewaut D, De Keyser F, Cuvelier C, et al. Distinctive activated cellular subsets in colon from patients with Crohn’s disease and ulcerative colitis. Scand J Gastroenterol. 1998 Jul;33(7):743–748.
   PubMed Web of Science ®Google Scholar
• Pang M, Abe T, Fujihara T, et al. Up-regulation of alphaEbeta7, a novel integrin adhesion molecule, on T cells from systemic lupus erythematosus patients with specific epithelial involvement. Arthritis Rheum. 1998 Aug;41(8):1456–1463. doi:10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0.
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122–1130.
   PubMed Web of Science ®Google Scholar
• Danilenko DM, Wang H. The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk. Toxicol Pathol. 2012;40(2):272–287.
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996 Nov;111(5):1373–1380.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005 Jun 16;352(24):2499–2507.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Ghosh S, Panes J, et al. 861 safety and efficacy of Pf-00547,659, a fully human anti-MAdCAM antibody, in ulcerative colitis. Results of a first in human study. Gastroenterology. 2009;136(5 Suppl 1):A–132.
   Google Scholar
• Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 2009 May;157(2):281–293.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. American Gastroenterological Association. 2008 Dec;6(12):1370–1377.
   Web of Science ®Google Scholar
• Wei X, Wang Y, Fuh F, et al. Pharmacokinetic and pharmacodynamic modeling of the relationship between serum rhumab β7 levels and β7 receptor occupancy in phase I patients with ulcerative colitis [abstract PII-74]. Clin Pharmacol Ther. 2012;91(suppl 1):80.
   Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26;384(9940):309–318.
   PubMed Web of Science ®Google Scholar
• ClinicaTrials.gov. Open-label extension and safety study for patients with ulcerative colitis previously enrolled in Etrolizumab phase III studies. [Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02118584
   Google Scholar
• ClinicaTrials.gov. A study comparing the efficacy and safety of Etrolizumab with Adalimumab and placebo in patients with moderate to severe ulcerative colitis in patients naive to TNF inhibitors (study #1). [Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02163759
   Google Scholar
• ClinicaTrials.gov.A study comparing the efficacy and safety of Etrolizumab to Infliximab in patients with moderate to severe ulcerative colitis who are naive to TNF inhibitors.[Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02136069
   Google Scholar
• ClinicaTrials.gov. A study comparing the efficacy and safety of Etrolizumab with Adalimumab and placebo in patients with moderate to severe ulcerative colitis in patients naive to TNF inhibitors (study #2). [Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02171429
   Google Scholar
• ClinicaTrials.gov. A study of the efficacy and safety of Etrolizumab in ulcerative colitis patients who are refractory to or intolerant of TNF inhibitors. [Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02100696
   Google Scholar
• ClinicaTrials.gov. A study of the efficacy and safety of Etrolizumab treatment in maintenance of disease remission in ulcerative colitis participants who are naive to tumor necrosis factor (TNF) inhibitors. [Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02165215
   Google Scholar
• ClinicaTrials.gov. A study of the safety and efficacy of Etrolizumab in patients with moderately to severely active Crohn’s disease. [Cited 2015 Dec 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02394028
   Google Scholar
• ClinicaTrials.gov. A study to evaluate pain, tolerability, safety, and usability of a single self-administered Etrolizumab by auto-injector in healthy participants. [Cited 2016 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02629744
   Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar